A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Upadacitinib (Primary) ; Dupilumab
Indications Atopic dermatitis
Focus Registrational; Therapeutic Use
Acronyms Level Up
Sponsors AbbVie

Most Recent Events

25 Sep 2024 According to an AbbVie media release, data from this study will be presented EADV 2024.
01 Sep 2024 This trial has been completed in Greece (global end date : 2024-08-08), according to European Clinical Trials Database
22 Aug 2024 This trial has been completed in Belgium (global end date : 2024-08-08), according to European Clinical Trials Database .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight